NXL103
NXL103 (formerly XRP 2868) is an experimental drug candidate under development by Novexel. It is an oral streptogramin antibiotic that has potent in vitro activity against certain Gram positive bacteria including methicillin resistant Staphylococcus aureus (MRSA) as well as the important respiratory pathogens including penicillin-, macrolide- and quinolone-resistant strains.[1][2] It is a combination of linopristin and flopristin.[3]
| Combination of | |
|---|---|
| Linopristin | antibiotic |
| Flopristin | antibiotic |
| Clinical data | |
| Other names | NXL103; XRP 2868 |
| Identifiers | |
| CAS Number | |
Clinical trials
Positive results have been reported from a phase II trial comparing it with amoxicillin.[1] Another phase II trial will be run in 2010 comparing it with linezolid for treatment of acute bacterial skin and skin structure infections (ABSSSI).[4]
References
- Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia, drugs.com
- Pankuch GA, Hoellman D, Bryskier A, Lowther J, Appelbaum PC (November 2006). "Effects of various media on the activity of NXL103 (formerly XRP 2868), a new oral streptogramin, against Haemophilus influenzae". Antimicrobial Agents and Chemotherapy. 50 (11): 3914–6. doi:10.1128/AAC.00587-06. PMC 1635171. PMID 17065630.
- NXL103 at Novexel.com
- Clinical trial number NCT00949130 for "Comparative Study of NXL103 Versus Linezolid in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)" at ClinicalTrials.gov
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.